N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma

BMC Cancer

Table 2 Abundance of 12 N-glycan structures attached to serum proteins in IgD MM, LCMM patients and healthy CTRs

Structures	Healthy CTR	IgD MM	LCMM	P1	P2
Structures	(n = 42)	(κ 1, λ 19)	(κ 19, λ 22)	P1	P2
NGA2F	7.79 ± 1.94	5.77 ± 2.04	6.93 ± 3.00	<0.001	NS
NGA2FB	1.30 ± 0.45	1.06 ± 0.80	0.90 ± 0.54	NS	NS
NG1(6)A2F	6.32 ± 1.11	3.17 ± 1.09	3.44 ± 1.40	<0.001	NS
NG1(3)A2F	5.61 ± 1.22	3.53 ± 0.97	4.15 ± 0.84	<0.001	0.013
NA2	38.76 ± 3.06	44.07 ± 6.20	47.49 ± 6.43	0.001	NS
NA2F	20.14 ± 2.54	18.50 ± 9.56	14.76 ± 5.63	NS	NS
NA2FB	6.21 ± 1.40	4.85 ± 3.37	2.52 ± 2.40	NS	0.009
NA3	7.80 ± 1.96	9.84 ± 3.26	10.08 ± 3.51	0.016	NS
NA3Fb	2.68 ± 1.28	4.57 ± 3.14	5.04 ± 3.21	0.017	NS
NA3F2	0.34 ± 0.13	0.42 ± 0.16	0.46 ± 0.23	0.035	NS
NA4	1.69 ± 0.61	2.97 ± 0.95	3.01 ± 1.36	<0.001	NS
NA4Fb	0.47 ± 0.24	1.25 ± 0.89	1.22 ± 0.73	0.001	NS

Note: Quantitative data are expressed as the means ± standard deviation; P1: comparison between IgD MM patients and healthy CTR
P2: comparison between IgD MM and LCMM patients
Abbreviations: IgD MM IgD multiple myeloma, LCMM light chain multiple myeloma, CTR control subject, NS non-significant

ISSN: 1471-2407